about
Stem Cell Modeling of Core Binding Factor Acute Myeloid LeukemiaEmerging patterns of somatic mutations in cancerNext generation sequencing of acute myeloid leukemia: influencing prognosis.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 casesMinimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.Clinical case of acute myeloblastic leukemia with t(8;21)(q22;q22) in a patient with Klinefelter's syndrome.Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemiaInfluence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemiaMyeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant.Effect of body mass index on the outcome of children with acute myeloid leukemia.Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotypeTime-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AMLAmplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11.Older patients with acute myeloid leukemia.Upfront therapy of acute myeloid leukemia.Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.Vascular endothelial growth factor signaling in acute myeloid leukemia.Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia.Fusion genes in malignant neoplastic disorders of haematopoietic system.Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia.Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study.Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries.Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML.A pipeline with multiplex reverse transcription polymerase chain reaction and microarray for screening of chromosomal translocations in leukemiaFrequency of TP53 Mutations and its Impact on Drug Sensitivity in Acute Myeloid Leukemia?A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice.Prognosis of patients with t(8;16)(p11;p13) acute myeloid leukemia.Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
P2860
Q26765858-8BF05F78-1A5F-4670-93E7-BB2E7D698635Q27014126-B72F0EEA-0284-499D-9D91-DB9156BA589FQ27690776-46BFEFAE-E1DD-4398-A0BD-DB44AF39F164Q33832709-0D731AF5-119D-41C0-9EA3-7ACB96A80B02Q33873844-F1958794-441F-49D3-B062-BF9C2797F788Q34044905-74C1ECDE-401B-4BC0-85B6-C55D01188126Q34193514-AE6CFC9B-63E1-4D34-92A2-DEDDF1887223Q34255090-1F64FC33-EA49-4BAD-997F-D9CBEFCD7455Q34260505-935E9EBD-82FA-4EB6-81C5-63F569287F99Q34293391-A2BD13DA-6DD4-4E8D-AA0C-84B40ADCE786Q34577037-AE9C9231-4F2B-4E70-9DD4-3D340FF88A93Q35209900-BBBFE4B1-DADF-4865-85F0-BF41DB6F89D6Q35567940-DE73FB9A-1834-48E5-A586-4B4CD09B3194Q35585976-69BC5C25-20E9-4DC8-8D59-2700B0BAB256Q35671452-F4DAB061-64FD-43C4-88CA-A27EAEB0B5F8Q35932199-008D7D2C-8D4A-4E28-93E9-7F095A917657Q36210124-126AE1FE-C3D9-405E-807F-CCCA4598E2AEQ36254242-EFE17B3A-B3C4-4E76-89FE-FBC0D885A16EQ37079016-03C6C6E6-639F-454A-B19F-CE6BEEA89BEDQ37179371-3A165922-F281-4C41-A13C-96FF740B98D9Q37181624-A183FA57-0C4C-4C70-9FF9-7CA8A5DE3283Q37810969-0BA9C5A6-C539-4987-923A-7ABA1980279BQ37897183-20BED38F-C0ED-422D-88B3-A6BB3F6BBC2AQ37934964-DEE141C8-2477-4585-A191-D91DE944E7BAQ38029546-6E464727-F607-403B-B164-D752712857BAQ38315894-0889EA4A-5936-4E69-88C4-85E62027E2F3Q38731027-C1DB4B17-2074-4051-88FC-9C146C728F29Q39192183-EF1DD742-75C0-47C9-B3B8-4B9A36E521BCQ39449424-20F2C764-BF20-46F5-98E0-D0416334A2A4Q40634949-C4774489-0AAB-4B88-98C8-2DAAB986C86BQ41895366-14733AD1-0DEB-4420-8698-F8DC85E375ACQ42127851-6B6F69D3-E444-4333-9678-1F5CB2F6239FQ42176391-93DD3694-59A3-4580-895B-2B65D406056DQ42593097-18103485-7690-4012-BA69-ABB0EE282D56Q43574379-CAFE0E0A-EC68-45E8-BFC3-B4597C6039DCQ44059514-1741A471-2991-42D9-A1B9-C7DC8E40A4E6Q45800079-A30EA476-94F5-4246-86B1-60094E93DBB4Q47235517-59262634-A5D7-4D3E-99E8-AF0320A0CFC4Q48590181-62796EDA-E733-45AC-B298-FA8387F5D4D4Q48882411-56EF25B7-178A-45ED-8D95-BF7DE23B655D
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Independent prognostic factors for AML outcome.
@ast
Independent prognostic factors for AML outcome.
@en
Independent prognostic factors for AML outcome.
@nl
type
label
Independent prognostic factors for AML outcome.
@ast
Independent prognostic factors for AML outcome.
@en
Independent prognostic factors for AML outcome.
@nl
prefLabel
Independent prognostic factors for AML outcome.
@ast
Independent prognostic factors for AML outcome.
@en
Independent prognostic factors for AML outcome.
@nl
P1476
Independent prognostic factors for AML outcome.
@en
P2093
David Grimwade
Robert K Hills
P304
P356
10.1182/ASHEDUCATION-2009.1.385
P577
2009-01-01T00:00:00Z